Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms
Authors Urban-Kowalczyk M, PigoÅska J, Åmigielski J
Received 30 April 2015
Accepted for publication 20 May 2015
Published 6 August 2015 Volume 2015:11 Pages 2023—2031
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ryouhei Ishii
Peer reviewer comments 2
Editor who approved publication: Dr Roger Pinder
MaÅgorzata Urban-Kowalczyk,1 Justyna PigoÅska,2 Janusz Åmigielski3
1Department of Affective and Psychotic Disorders, Medical University of ÅódÅº, ÅódÅº, Poland; 2Department of Neurology and Movement Disorders, Medical University of ÅódÅº, ÅódÅº, Poland; 3Department of Geriatrics, Healthy Ageing Research Centre (HARC), Medical University of ÅódÅº, ÅódÅº, Poland
Objectives: The causes and nature of insensitivity to pain in schizophrenia remain unknown. The role of endorphins and the association of cognitive dysfunction and negative symptoms are postulated.
Methods: In this study, 43 patients with schizophrenia, five first-degree relatives, and 34 healthy controls were examined. Participants’ plasma concentrations of substance P, β-endorphin, and calcitonin gene-related peptide (CGRP) were assessed. In patients, the Trail-Making Test, the Color Reading Interference Test (Stroop test), and the Positive and Negative Syndrome Scale Negative Syndrome subscale (PANSS N) test were performed. We also evaluated pain threshold using nociceptive reflex (RTIII) testing.
Results: The mean β-endorphin concentration was about 20% higher in patients than in healthy controls (P<0.05). CGRP concentrations were significantly higher in patients than in controls (5.34 ng/mL versus 4.16 ng/mL; P<0.01). Subjects treated with antipsychotic polytherapy had higher concentrations of CGRP than did patients treated with second-generation antipsychotic monotherapy (5.92 ng/mL versus 5.02 ng/mL; P<0.05). There were no correlations between any biochemical parameters and Trail-Making Test, Stroop test, and PANSS N scores. There were no differences in RTIII among study groups. Strong negative correlation (P<0.001) was found between PANSS N scores and subjective pain threshold on the right lower limb.
Conclusion: The insensitivity to pain in schizophrenia is a complex phenomenon that is probably not related to changes in nociceptive pathways. Increase in β-endorphin level may be related to this issue, but it is uncertain if such concentration ensures analgesic effect. It is unknown if patients with schizophrenia in fact experience less pain. Cognitive impairment and excess negative symptoms may strongly influence the patient’s expression of pain.
Keywords: schizophrenia, endorphin, substance P, calcitonin gene-related peptide, working memory, negative symptoms
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]